Kawakami, H.; Nishikawa, K.; Shimokawa, T.; Fujitani, K.; Tamura, S.; Endo, S.; Kobayashi, M.; Kawada, J.; Kurokawa, Y.; Tsuburaya, A.;
et al. Histology Classification Highlights Differences in Efficacy of S-1 versus Capecitabine, in Combination with Cisplatin, for HER2-Negative Unresectable Advanced or Recurrent Gastric Cancer with Measurable Disease. Cancers 2022, 14, 5673.
https://doi.org/10.3390/cancers14225673
AMA Style
Kawakami H, Nishikawa K, Shimokawa T, Fujitani K, Tamura S, Endo S, Kobayashi M, Kawada J, Kurokawa Y, Tsuburaya A,
et al. Histology Classification Highlights Differences in Efficacy of S-1 versus Capecitabine, in Combination with Cisplatin, for HER2-Negative Unresectable Advanced or Recurrent Gastric Cancer with Measurable Disease. Cancers. 2022; 14(22):5673.
https://doi.org/10.3390/cancers14225673
Chicago/Turabian Style
Kawakami, Hisato, Kazuhiro Nishikawa, Toshio Shimokawa, Kazumasa Fujitani, Shigeyuki Tamura, Shunji Endo, Michiya Kobayashi, Junji Kawada, Yukinori Kurokawa, Akira Tsuburaya,
and et al. 2022. "Histology Classification Highlights Differences in Efficacy of S-1 versus Capecitabine, in Combination with Cisplatin, for HER2-Negative Unresectable Advanced or Recurrent Gastric Cancer with Measurable Disease" Cancers 14, no. 22: 5673.
https://doi.org/10.3390/cancers14225673
APA Style
Kawakami, H., Nishikawa, K., Shimokawa, T., Fujitani, K., Tamura, S., Endo, S., Kobayashi, M., Kawada, J., Kurokawa, Y., Tsuburaya, A., Yoshikawa, T., Sakamoto, J., Satoh, T., & on behalf of the HERBIS-2, HERBIS-4A and XParTS II Study Investigators.
(2022). Histology Classification Highlights Differences in Efficacy of S-1 versus Capecitabine, in Combination with Cisplatin, for HER2-Negative Unresectable Advanced or Recurrent Gastric Cancer with Measurable Disease. Cancers, 14(22), 5673.
https://doi.org/10.3390/cancers14225673
